Ocera Therapeutics, Inc. (OCRX) saw its loss narrow to $6.68 million, or $0.28 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $7.51 million, or $0.36 a share.
The company has not recorded any revenues for the current quarter. However, it has reported a revenue of $0.03 million for the previous year period.
Operating loss for the quarter was $6.43 million, compared with an operating loss of $7.27 million in the previous year period.
"To date, 2017 has been very eventful for Ocera with a successful Phase 1 study of oral OCR-002 in cirrhotic patients in January followed by the completion of our STOP-HE Phase 2b clinical trial of IV OCR-002 and subsequent data read out," said Linda Grais, M.D., chief executive officer of Ocera. "The data from STOP-HE confirmed that hyperammonemia is correlated with the severity of HE symptoms and that OCR-002 correlates with faster reduction of ammonia, and with clinical improvement."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
